Roche R&D Center China (RRDCC)

Roche R&D Center China (RRDCC)
Media Visit to Roche in China
Shanghai 30 October 2005
Andreas Tschirky, Ph.D.
Head of Roche R&D Center (China) Ltd.

Roche recognizes changes in China
• Strong economic development over the last 20 years
• Reorganization of Healthcare System
(e.g. implementation of GCP and GLP in Hospitals,
re-organization of Chinese Pharmaceutical industry)
• Implementation of new laws
(e.g. intellectual property law and regulations)
•Re-organization of Academic institutions towards Centers of excellence
•Promotion of Hi-Technology (e.g. Bio-Technology)
• Shanghai: the Biotechnology hub of China
• Central and local government support innovation based industries
• Increasing number of highly educated Chinese (and returnees) in drug discovery
research

Shanghai and Pudong

The ZJ Pharma Valley
r

Contribute to ZJ - HiTech Park growth
ZhangJiang Pharma Valley
Shanghai Roche Pharmaceutical Ltd
Southern Genomics Center
Shiguang Hospital
Shanghai Institute of Materia Medica
Shanghai TCM University
Roche R&D Center (China) Ltd
Source: ZJ HiTech Park

China IPR
• Patent law established in 1985
• 1 st Revision in 1992
– Expanded patent coverage to substance, formulation etc.
– Extended coverage time to 20 years
– Enforce the execution
• 2 nd Revision in 2000
– Prepare for WTO
– Improved patent application, evaluation and approval process
– Strengthen patent enforcement
• China patent applications
– 85-04: 2.289 Mio, annual growth rate 18.9%
– 2004: 353 K

Roche R&D Center (China) Co. Ltd
• Owned by Roche
• Is a part of the Roche Global Research
• Located at Shanghai ZJHT Park
• Initially will be staffed with 40 scientists
• Conduct medicinal chemistry in lead generation
and optimization as a part of Roche Global Research
• Collaborate and create partnership in drug discovery
• Create and protect IP in China
• Strong co-operation with SRPL

Establishment of RRDCC
• Building infrastructure
• Research infrastructure
• Recruitment
Feb 04
Site Selected
Oct 04
Site Opened
Nov 04
Site Setup
Advertising… Hiring… Training
Jan 04
Site Announcement
July 04
Site Construction
Dec 04
Site Operation

Roche
R&D Collaboration Projects in China
Project Description
Collaboration Partner
Schizophrenia related genes
Diabetes II/ Obesity related genes
Alzheimer’s disease related genes
Diabetes II/ Obesity (Hypertension)
Obesity / Hypertension
China Human Genome Center, Shanghai
China Human Genome Center, Shanghai
China Human Genome Center, Beijing
China Human Genome Center, Beijing
Sino-German Genome Center, Beijing
Chronic Obstructive Pulmonary Disease Shanghai
Chemistry Outsourcing (Intermediates)Shanghai Institute of Organic Chemistry
Total Investment >4.5 million USD in the past few years

Outlook: RRDCC as Platform organization
Co-operation
support functions
(SRPL)
Outsourcing
&
Project management
RRDCC
In-house research
&
Joint projects
In-licensing support
(IPR)
Communication with
Authorities and KOL
Training
&
Technology transfer
Roche is sending a very strong message to both the Chinese authorities and the scientific community
throughout the country that we share their vision of the future in which China will play an increasingly
important role in healthcare R&D

Potential new “Biotechnology valleys” in China
Major Pharmaceutical companies
Hospitals
Academic
Competence Centers
&
Investors
(VC, Banks et al.)
Biotech Startups
Ref.: Boston, San Diego

Summary
• As a pioneer in Drug discovery among MNCs in China, Roche
understands itself as a reliable partner to Government, Academia
and Biotech industry.
•The creation of RRDCC represents a major long-term commitment to
China and reinforces the importance of China as a global player in
the field of biomedical science as and a growing market for our
healthcare products.
• Roche’s commitment is also based on confidence in China’s
embrace of WTO principles and responsible approach to intellectual
property protection.